Emile, Jean-François

Foamy Macrophages from Tuberculous Patients' Granulomas Constitute a Nutrient-Rich Reservoir for M. tuberculosis Persistence

Peyron, P., Vaubourgeix, J., Poquet, Y., Levillain, F., Botanch, C., Bardou, F., Daffé, M., Emile, J.-F., Marchou, B., Cardona, P.-J., et al. (2008) · PLoS Pathogens

Tuberculosis Research and EpidemiologyMycobacterium research and diagnosis

Cited by 751

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation

Gastrointestinal Tumor Research and TreatmentImmune Cell Function and Interaction

Cited by 302

Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease

Bustamante, J., Arias, A. A., Vogt, G., Picard, C., Galicia, L. B., Prando, C., Grant, A. V., Marchal, C. C., Hubeau, M., Chapgier, A., et al. (2011) · Nature Immunology

Immunodeficiency and Autoimmune DisordersTuberculosis Research and Epidemiology

Cited by 287

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas

Pilati, C., Shinde, J., Alexandrov, L. B., Assié, G., André, T., Hélias‐Rodzewicz, Z., Ducoudray, R., Le Corre, D., Zucman‐Rossi, J., Emile, J., et al. (2017) · The Journal of Pathology

Genetic factors in colorectal cancerCancer Genomics and Diagnostics

Cited by 150

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 108

Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer

Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 68

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer

Le Corre, D., Ghazi, A., Balogoun, R., Pilati, C., Aparicio, T., Martin-Lannerée, S., Marisa, L., Djouadi, F., Poindessous, V., Crozet, C., et al. (2019) · eBioMedicine

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 48

LBA1 Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial

Tougeron, D., Emile, J. F., Bodere, A., Barbier, E., Bez, J., Dourthe, L. M., Perrier, H., Corbinais, S., Le Brun-Ly, V., Bideau, K., et al. (2024) · Annals of Oncology

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 6